Compounds > cyc 202
Page last updated: 2024-09-04

cyc 202 and Prostatic Neoplasms

cyc 202 has been researched along with Prostatic Neoplasms in 12 studies

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (66.67)29.6817
2010's4 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, MC; Chien, WS; Day, CH; Hsu, HH; Huang, CY; Lin, TH; Padma, VV; Shen, CH; Velmurugan, BK; Wu, HC1
Agostinelli, E; Arisan, ED; Calcabrini, A; Coker-Gurkan, A; Obakan, P; Unsal, NP1
Arisan, ED; Berrak, O; Coker-Gürkan, A; Obakan-Yerlikaya, P; Palavan-Unsal, N1
Cheng, JQ; Chu, B; Djeu, J; Mohapatra, S; Pledger, WJ; Zhao, X1
Helenius, MA; Jänne, OA; Linja, MJ; Manni, V; Sahu, B; Visakorpi, T; Waltering, KK1
Adams, CE; Edwards, J; Fyffe, G; Heng, SJ; Horgan, PG; Leung, HY; McCall, P; Seywright, M; Tannahill, C; Underwood, MA; Willder, JM1
Juang, JL; Lin, H; Wang, PS1
Barth, P; Göke, R; Lankat-Buttgereit, B; Samans, B; Schmidt, A1
Chu, B; Mohapatra, S; Pledger, WJ; Zhao, X1
Balk, SP; Bubley, GJ; Chen, S; Xu, Y; Yuan, X1
Chen, MJ; Hsu, JM; Kan, SF; Pu, HF; Wang, PS; Yu, CH1
Fischer, K; Hescheler, J; Sauer, H; Wartenberg, M1

Other Studies

12 other study(ies) available for cyc 202 and Prostatic Neoplasms

ArticleYear
KHC-4 inhibits β-catenin expression in prostate cancer cells.
    Biotechnic & histochemistry : official publication of the Biological Stain Commission, 2019, Volume: 94, Issue:5

    Topics: Antineoplastic Agents; beta Catenin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Humans; Male; Morpholines; Prostatic Neoplasms; Quinolones; Roscovitine; Signal Transduction

2019
CDK inhibitors induce mitochondria-mediated apoptosis through the activation of polyamine catabolic pathway in LNCaP, DU145 and PC3 prostate cancer cells.
    Current pharmaceutical design, 2014, Volume: 20, Issue:2

    Topics: Apoptosis; Caspases; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Male; Mitochondria; Polyamines; Prostatic Neoplasms; Protein Kinase Inhibitors; Purines; Receptors, Androgen; Roscovitine

2014
mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
    Apoptosis : an international journal on programmed cell death, 2016, Volume: 21, Issue:10

    Topics: Apoptosis; Autophagy; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Receptors, Androgen; Roscovitine; Signal Transduction; TOR Serine-Threonine Kinases

2016
Apoptosis of metastatic prostate cancer cells by a combination of cyclin-dependent kinase and AKT inhibitors.
    The international journal of biochemistry & cell biology, 2009, Volume: 41, Issue:3

    Topics: Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Caspase 9; Cell Line, Tumor; Chlorpropamide; Chromones; Cyclin-Dependent Kinase 9; Cyclin-Dependent Kinases; Dichlororibofuranosylbenzimidazole; DNA; Drug Synergism; Humans; Male; Membrane Proteins; Mitochondria; Morpholines; Nucleic Acid Synthesis Inhibitors; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Purines; RNA, Small Interfering; Roscovitine; X-Linked Inhibitor of Apoptosis Protein

2009
Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
    Cancer research, 2009, Oct-15, Volume: 69, Issue:20

    Topics: Androgens; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Chromatin Immunoprecipitation; Dose-Response Relationship, Drug; Fluorescent Antibody Technique; Gene Expression Profiling; Humans; Male; Neoplasms, Hormone-Dependent; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Purines; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Roscovitine

2009
Androgen receptor phosphorylation at serine 515 by Cdk1 predicts biochemical relapse in prostate cancer patients.
    British journal of cancer, 2013, Jan-15, Volume: 108, Issue:1

    Topics: Aged; Biomarkers, Tumor; CDC2 Protein Kinase; Disease-Free Survival; Humans; Male; MAP Kinase Signaling System; Phosphorylation; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Purines; Receptors, Androgen; Recurrence; Roscovitine; Serine

2013
Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis.
    The Journal of biological chemistry, 2004, Jul-09, Volume: 279, Issue:28

    Topics: 4-Butyrolactone; Apoptosis; Calcium; Caspase Inhibitors; Caspases; Cell Line, Tumor; Cyclin-Dependent Kinase 5; Cyclin-Dependent Kinases; Digoxin; Dipeptides; Enzyme Activation; Enzyme Inhibitors; Humans; Male; Nerve Tissue Proteins; Prostatic Neoplasms; Purines; RNA, Small Interfering; Roscovitine

2004
Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21(Waf1/Cip1).
    American journal of physiology. Cell physiology, 2004, Volume: 287, Issue:6

    Topics: Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Carcinoid Tumor; CDC2 Protein Kinase; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Endocrine Gland Neoplasms; Female; Humans; Insulinoma; Lung Neoplasms; Male; Pancreatic Neoplasms; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Purines; Retinoblastoma Protein; RNA-Binding Proteins; Roscovitine

2004
Accumulation of p53 and reductions in XIAP abundance promote the apoptosis of prostate cancer cells.
    Cancer research, 2005, Sep-01, Volume: 65, Issue:17

    Topics: 2-Aminopurine; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 9; Caspases; Cell Line, Tumor; Cyclin-Dependent Kinases; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Protein Kinase Inhibitors; Proteins; Purines; Roscovitine; Tumor Suppressor Protein p53; X-Linked Inhibitor of Apoptosis Protein

2005
Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1.
    Proceedings of the National Academy of Sciences of the United States of America, 2006, Oct-24, Volume: 103, Issue:43

    Topics: Androgens; CDC2 Protein Kinase; Cell Line, Tumor; Humans; Male; Phosphorylation; Phosphoserine; Prostatic Neoplasms; Protein Kinase Inhibitors; Purines; Receptors, Androgen; Roscovitine; Transcription, Genetic

2006
Anti-proliferative effects of evodiamine on human prostate cancer cell lines DU145 and PC3.
    Journal of cellular biochemistry, 2007, May-01, Volume: 101, Issue:1

    Topics: Androgens; Apoptosis; Carcinoma; Caspase 3; Caspase 8; Caspase 9; CDC2 Protein Kinase; Cell Division; Cell Line, Tumor; Culture Media; Cyclin B; Cyclin B1; DNA Fragmentation; DNA, Neoplasm; Dose-Response Relationship, Drug; Flow Cytometry; G2 Phase; Humans; L-Lactate Dehydrogenase; Male; Plant Extracts; Prostatic Neoplasms; Purines; Quinazolines; Roscovitine

2007
Modulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by cell cycle inhibitors.
    Biochimica et biophysica acta, 2002, Feb-13, Volume: 1589, Issue:1

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; Enzyme Inhibitors; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Male; Mimosine; Mitomycin; Prostatic Neoplasms; Purines; Roscovitine; Staurosporine; Tumor Cells, Cultured; Tumor Suppressor Proteins

2002